The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta‐Analysis of More Than 20 000 Patients
Open accessAbstract
Background: The monoclonal antibody bevacizumab effectively inhibits angiogenesis in several types of cancers by blocking vascular endothelial growth factor. However, life‐threatening cardiovascular adverse effects could limit its use and may warrant specific follow‐up strategies. Methods and Results: We systematically searched MEDLINE, Cochrane, EMBASE , and Web of Science for randomized controlled trials published until November 2016 that assessed patients with cancer treated with or without bevacizumab in addition to standard chemotherapy. A total of 20 050 patients with a broad range of cancer types from 22 studies were included in this analysis (10 394 in the bevacizumab group and 9656 in the control group). The risks of arterial and venous adverse events were higher in the bevacizumab groups (relative risk [RR], 1.37; 95% CI , 1.10–1.70 [ P =0.004] and RR , 1.29; 95% CI , 1.12–1.47 [ P <0.001], respectively), and more arterial adverse events occurred in patients taking high‐dose bevacizumab regimens. Bevacizumab treatment was associated with the highest risk of cardiac and cerebral ischemia in the high‐dose bevacizumab groups ( RR , 4.4; 95% CI , 1.59–12.70 [ P =0.004] and RR , 6.67; 95% CI , 2.17–20.66 [ P =0.001], respectively). In addition, the risk of bleeding and arterial hypertension were higher in the bevacizumab groups ( RR , 2.74; 95% CI , 2.38–3.15 [ P <0.001] and RR , 4.73; 95% CI , 4.15–5.39 [ P <0.00001], respectively), with higher values for patiens taking high‐dose regimens. Conclusions: Treatment with bevacizumab increases the risk of arterial adverse events, particularly cardiac and cerebral ischemia, venous adverse events, bleeding, and arterial hypertension. This risk is additionally increased with high doses of bevacizumab. Further studies should determine the appropriate options for cardio‐oncology management. Clinical Trial Registration: URL : https://www.crd.york.ac.uk . Unique identifier: PROSPERO ( CRD 42016054305).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PRISMA-P Group, Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015) · Systematic Reviews · doi:10.1186/2046-4053-4-1 · Cited by 26,223
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166
Tebbutt, N. C., Wilson, K., Gebski, V. J., Cummins, M. M., Zannino, D., van Hazel, G. A., Robinson, B., Broad, A., Ganju, V., Ackland, S. P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.7723 · Cited by 413
Soria, J.-C., Mauguen, A., Reck, M., Sandler, A. B., Saijo, N., Johnson, D. H., Burcoveanu, D., Fukuoka, M., Besse, B., & Pignon, J.-P. (2013) · Annals of Oncology · doi:10.1093/annonc/mds590 · Cited by 314
Nitrite regulates hypoxic vasodilation via myoglobin-dependent nitric oxide generation
Totzeck, M., Hendgen-Cotta, U. B., Luedike, P., Berenbrink, M., Klare, J. P., Steinhoff, H.-J., Semmler, D., Shiva, S., Williams, D., Kipar, A., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.087155 · Cited by 202
Self-citation
Cited by
Bikdeli, B., Madhavan, M. V., Jimenez, D., Chuich, T., Dreyfus, I., Driggin, E., Nigoghossian, C. D., Ageno, W., Madjid, M., Guo, Y., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.031 · Cited by 2,885
Cancer-associated venous thromboembolism
Khorana, A. A., Mackman, N., Falanga, A., Pabinger, I., Noble, S., Ageno, W., Moik, F., & Lee, A. Y. Y. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00336-y · Cited by 470
Systemic treatment of hepatocellular carcinoma: An EASL position paper
Bruix, J., Chan, S. L., Galle, P. R., Rimassa, L., & Sangro, B. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.004 · Cited by 380
Michel, L., Mincu, R. I., Mahabadi, A. A., Settelmeier, S., Al-Rashid, F., Rassaf, T., & Totzeck, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1631 · Cited by 265
Self-citation
Metadata
- Authors
- Totzeck, M., Mincu, R. I., & Rassaf, T.
- Venue
- Journal of the American Heart Association
- Published
- 2017-08-02
- Volume
- 6
- Issue
- 8
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2742729000
- Cited by
- 192
- References
- 8
- FWCI
- 8.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta‐Analysis of More Than 20 000 Patients. https://app.cochat.ai/papers/10.1161/jaha.117.006278
- The paper
- Totzeck, M., Mincu, R. I., & Rassaf, T. (2017). Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta‐Analysis of More Than 20 000 Patients. Journal of the American Heart Association. https://doi.org/10.1161/jaha.117.006278
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.